Wilcock GK et al., 2018: The disputed re-analysis: the sponsor changed the primary analysis of the failed mild-AD trial before unblinding so that non-randomised monotherapy cohort comparisons became the primary outcomes, and reported significant benefits, including at the 4 mg 'placebo' dose.
As the originally intended analysis was unlikely to achieve its intended purpose, we modified the primary analyses and treatment comparisons in the TRx-237-005 Statistical Analysis Plan prior to database lock and unblinding
Methods, 'Statistical analysis'
Wilcock GK et al., 2018: The disputed re-analysis: the sponsor changed the primary analysis of the failed mild-AD trial before unblinding so that non-randomised monotherapy cohort comparisons became the primary outcomes, and reported significant benefits, including at the 4 mg 'placebo' dose. This row records the sponsor's position at full strength and is the core of the dispute. Study type: post-hoc/cohort re-analysis of a randomised phase 3 (NCT01689233, n=800). Comparator: non-randomised cohorts (100 mg BID monotherapy, n=79, vs 4 mg BID as randomised, n=396; 4 mg BID monotherapy, n=76, vs 4 mg BID add-on, n=297). Country: 108 sites, Canada/US/Australia/Europe. Funder: TauRx, which 'took the lead in study design, undertaking the study, data interpretation, and initial drafting'. Results claimed: ADAS-cog effect -3.14 (95% CI -5.32 to -0.97, p=0.0047) and ADCS-ADL 3.49 (0.66 to 6.30, p=0.0157). The paper itself states 'There was no evidence of any difference on any of the primary or secondary endpoints in the as-randomized analyses defined in the protocol.' Critique: MTC-085, MTC-084. Also filed as MTC-041 (claims C6, F1). Study type: controlled study.
